Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityNo recent work listed

Zheng Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8945-3107; OpenAlex author ID A5100724108. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2022: 2 papers

Papers 2

  1. Corynoxine suppresses pancreatic cancer growth primarily via ROS-p38 mediated cytostatic effects. Co-author DOI 10.1038/s41416-022-02002-2↗
  2. Curcumin Derivative C66 Suppresses Pancreatic Cancer Progression through the Inhibition of JNK-Mediated Inflammation. Last author DOI 10.3390/molecules27103076↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chunmei Wen · 1 shared paper, 2022 · strength 0.16
  2. Hongjin Chen · 1 shared paper, 2022 · strength 0.16
  3. Xiong Chen · 1 shared paper, 2022 · strength 0.16
  4. Qinbo Chen · 1 shared paper, 2022 · strength 0.16
  5. Xiang Zhou · 1 shared paper, 2022 · strength 0.16
  6. Guang Liang · 1 shared paper, 2022 · strength 0.16
  7. Jie Deng · 1 shared paper, 2022 · strength 0.16
  8. Percy David Papa Akuetteh · 1 shared paper, 2022 · strength 0.16
  9. Qingqing Ruan · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.